485 related articles for article (PubMed ID: 26257166)
21. Tenofovir-emtricitabine therapy for the prevention of hepatitis B recurrence in four patients after liver transplantation.
McGonigal KH; Bajjoka IE; Abouljoud MS
Pharmacotherapy; 2013 Sep; 33(9):e170-6. PubMed ID: 23744810
[TBL] [Abstract][Full Text] [Related]
22. Antiviral prophylaxis against hepatitis B recurrence after liver transplantation: Current concepts.
Orfanidou A; Papatheodoridis GV; Cholongitas E
Liver Int; 2021 Jul; 41(7):1448-1461. PubMed ID: 33656809
[TBL] [Abstract][Full Text] [Related]
23. Minimization of anti-hepatitis B surface antigen immunoglobulins for prophylaxis of hepatitis B viral recurrence in the first month after liver transplantation: the meaning of HBsAg quantitative level at the time of transplant.
Tandoi F; Nada E; Pittaluga F; Fop F; Lupo F; Romagnoli R; Salizzoni M
Transplant Proc; 2014 Sep; 46(7):2308-11. PubMed ID: 25242775
[TBL] [Abstract][Full Text] [Related]
24. Section 14. Combination of entecavir plus low-dose on-demand hepatitis B immunoglobulin is effective with very low hepatitis B recurrence after liver transplantation.
Hu TH; Chen CL; Lin CC; Wang CC; Chiu KW; Yong CC; Liu YW; Eng HL
Transplantation; 2014 Apr; 97 Suppl 8():S53-9. PubMed ID: 24849836
[TBL] [Abstract][Full Text] [Related]
25. Randomized trial of emtricitabine/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation.
Teperman LW; Poordad F; Bzowej N; Martin P; Pungpapong S; Schiano T; Flaherty J; Dinh P; Rossi S; Subramanian GM; Spivey J
Liver Transpl; 2013 Jun; 19(6):594-601. PubMed ID: 23447407
[TBL] [Abstract][Full Text] [Related]
26. Prevention of hepatitis B virus reinfection in liver transplant recipients.
Roche B; Samuel D
Intervirology; 2014; 57(3-4):196-201. PubMed ID: 25034488
[TBL] [Abstract][Full Text] [Related]
27. Clinical-pathological analysis of hepatitis B virus recurrence after liver transplantation in Chinese patients.
Gao YJ; Zhang M; Jin B; Meng FP; Ma XM; Liu ZW; Su HB; Zhao JM; Li HW
J Gastroenterol Hepatol; 2014 Mar; 29(3):554-60. PubMed ID: 24117714
[TBL] [Abstract][Full Text] [Related]
28. Prophylaxis against hepatitis B virus recurrence after liver transplantation: a registry study.
Shen S; Jiang L; Xiao GQ; Yan LN; Yang JY; Wen TF; Li B; Wang WT; Xu MQ; Wei YG
World J Gastroenterol; 2015 Jan; 21(2):584-92. PubMed ID: 25593480
[TBL] [Abstract][Full Text] [Related]
29. Posttransplantation prophylaxis with primary high-dose hepatitis B immunoglobulin monotherapy and complementary preemptive antiviral add-on.
Hwang S; Ahn CS; Song GW; Kim KH; Moon DB; Oh HB; Lim YS; Lee HC; Ha TY; Jung DH; Chung YH; Lee SG
Liver Transpl; 2011 Apr; 17(4):456-65. PubMed ID: 21445929
[TBL] [Abstract][Full Text] [Related]
30. Post-liver transplant hepatitis B prophylaxis: the role of oral nucleos(t)ide analogues.
Patterson SJ; Angus PW
Curr Opin Organ Transplant; 2009 Jun; 14(3):225-30. PubMed ID: 19373086
[TBL] [Abstract][Full Text] [Related]
31. Antiviral treatment for hepatitis B virus recurrence following liver transplantation.
Lee S; Kwon CH; Moon HH; Kim TS; Roh Y; Song S; Shin M; Kim JM; Park JB; Kim SJ; Joh JW; Lee SK
Clin Transplant; 2013; 27(5):E597-604. PubMed ID: 24093615
[TBL] [Abstract][Full Text] [Related]
32. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation.
Gane EJ; Angus PW; Strasser S; Crawford DH; Ring J; Jeffrey GP; McCaughan GW;
Gastroenterology; 2007 Mar; 132(3):931-7. PubMed ID: 17383422
[TBL] [Abstract][Full Text] [Related]
33. Successful clinical and virological outcomes of liver transplantation for HDV/HBV-related disease after long-term discontinuation of hepatitis B immunoglobulins.
Lenci I; Tariciotti L; Angelico R; Milana M; Signorello A; Manzia TM; Toti L; Tisone G; Angelico M; Baiocchi L
Clin Transplant; 2023 Jun; 37(6):e14971. PubMed ID: 36928864
[TBL] [Abstract][Full Text] [Related]
34. A new scheme with infusion of hepatitis B immunoglobulin combined with entecavir for prophylaxis of hepatitis B virus recurrence among liver transplant recipients.
Chen G; Liu H; Hu ZQ; Bai JH; Liu QY; Zhao YP; Gan XM; Wang F; Wang DD; Ma LJ; Li L
Eur J Gastroenterol Hepatol; 2015 Aug; 27(8):901-6. PubMed ID: 26011237
[TBL] [Abstract][Full Text] [Related]
35. Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates.
Gane EJ; Patterson S; Strasser SI; McCaughan GW; Angus PW
Liver Transpl; 2013 Mar; 19(3):268-74. PubMed ID: 23447403
[TBL] [Abstract][Full Text] [Related]
36. Anti-HBs response to hepatitis B immunoglobulin prophylaxis in liver transplant recipients.
Varghese J; Reddy MS; Cherian T; Vijaya S; Jayanthi V; Rela M
Indian J Gastroenterol; 2014 May; 33(3):226-30. PubMed ID: 24760685
[TBL] [Abstract][Full Text] [Related]
37. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis.
Angus PW; Patterson SJ; Strasser SI; McCaughan GW; Gane E
Hepatology; 2008 Nov; 48(5):1460-6. PubMed ID: 18925641
[TBL] [Abstract][Full Text] [Related]
38. Clinical outcomes and risk factors of hepatitis B virus recurrence in patients who received prophylaxis with entecavir and hepatitis B immunoglobulin following liver transplantation.
Kim YK; Kim SH; Lee SD; Park SJ
Transplant Proc; 2013 Oct; 45(8):3052-6. PubMed ID: 24157034
[TBL] [Abstract][Full Text] [Related]
39. Adefovir dipivoxil therapy in liver transplant recipients for recurrence of hepatitis B virus infection despite lamivudine plus hepatitis B immunoglobulin prophylaxis.
Akyildiz M; Karasu Z; Zeytunlu M; Aydin U; Ozacar T; Kilic M
J Gastroenterol Hepatol; 2007 Dec; 22(12):2130-4. PubMed ID: 18031370
[TBL] [Abstract][Full Text] [Related]
40. Monotherapy with tenofovir disoproxil fumarate for multiple drug-resistant chronic hepatitis B: 3-year trial.
Lim YS; Lee YS; Gwak GY; Byun KS; Kim YJ; Choi J; An J; Lee HC; Yoo BC; Kwon SY
Hepatology; 2017 Sep; 66(3):772-783. PubMed ID: 28370419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
